Drug intelligence / Profile preview

PHN033

Development stage: Unknown
Lead developer: PhytoHealth
Modality: Small Molecules
Administration: Oral

Overview

PHN033 is a botanical drug candidate developed by Phyto Health Corporation, currently in Phase 2 clinical trials for the treatment of diabetic nephropathy. It is a highly purified extract derived from the root of *Astragalus membranaceus*. The drug is designed to slow the progression of kidney damage in diabetic patients by exerting anti-inflammatory and anti-fibrotic effects, potentially reducing proteinuria and preserving glomerular filtration rates. As a botanical drug, it follows the regulatory pathway for complex mixtures of plant-derived compounds, aiming to address the underlying pathology of chronic kidney disease resulting from diabetes.

Brand names: 懷特糖寶White Sugar Treasure
Other names: Whiteboard Sugar TreasureHuai-Te Tang-Bao

Targets

TGFB1 (Transforming growth factor Beta-1 proprotein)

Beyond the preview

Go deeper on PHN033.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PHN033.

Explore the full profile